This HTML5 document contains 49 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dcthttp://purl.org/dc/terms/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
dbpedia-kohttp://ko.dbpedia.org/resource/
n13https://global.dbpedia.org/id/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
dbpedia-ukhttp://uk.dbpedia.org/resource/
n17http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
n16http://bn.dbpedia.org/resource/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:AdCLD-CoV19
rdf:type
wikidata:Q8386 dbo:Drug dbo:Vaccine dbo:ChemicalSubstance n17:ChemicalObject owl:Thing
rdfs:label
AdCLD-CoV19 AdCLD-CoV19 AdCLD-CoV19
rdfs:comment
AdCLD-CoV19는 대한민국 셀리드가 개발중인 코로나19 백신 후보물질이다. 현재 임상 2상 단계에 있다. AdCLD-CoV19 is a COVID-19 vaccine candidate developed by Cellid Co, a company from South Korea. A phase 1/2 trial of a single injection of AdCLD-CoV19 began in December 2020 in South Korea. In September 2021, a phase 1 trial began for a single injection of another version, named AdCLD-CoV19-1.Preclinical studies of a single dose in mice and non-human primates for this vaccine candidate were published in April 2022. In August 2022, a phase 2 trial of 1 or 2 doses of AdCLD-CoV19-1 was registered.
dct:subject
dbc:Viral_vector_vaccines dbc:Clinical_trials dbc:South_Korean_COVID-19_vaccines dbc:Science_and_technology_in_South_Korea
dbo:wikiPageID
68532309
dbo:wikiPageRevisionID
1118148287
dbo:wikiPageWikiLink
dbr:Severe_acute_respiratory_syndrome_coronavirus_2 dbr:COVID-19_vaccine dbc:Clinical_trials dbc:Viral_vector_vaccines dbr:Intramuscular_injection dbc:Science_and_technology_in_South_Korea dbc:South_Korean_COVID-19_vaccines
owl:sameAs
dbpedia-ko:AdCLD-CoV19 dbpedia-uk:AdCLD-CoV19 n13:G5tws n16:অ্যাডসিএলডি-কোভি১৯ wikidata:Q108415181
dbp:vaccineType
viral
dbp:wikiPageUsesTemplate
dbt:Infobox_drug dbt:Portal_bar dbt:Short_description dbt:Vaccines dbt:Vaccine-stub dbt:Scholia dbt:COVID19-vaccine-stub dbt:COVID-19_pandemic_sidebar dbt:COVID-19_pandemic dbt:Use_dmy_dates dbt:Reflist
dbp:routesOfAdministration
dbr:Intramuscular_injection
dbp:target
dbr:Severe_acute_respiratory_syndrome_coronavirus_2
dbp:type
vaccine
dbo:abstract
AdCLD-CoV19는 대한민국 셀리드가 개발중인 코로나19 백신 후보물질이다. 현재 임상 2상 단계에 있다. AdCLD-CoV19 is a COVID-19 vaccine candidate developed by Cellid Co, a company from South Korea. A phase 1/2 trial of a single injection of AdCLD-CoV19 began in December 2020 in South Korea. In September 2021, a phase 1 trial began for a single injection of another version, named AdCLD-CoV19-1.Preclinical studies of a single dose in mice and non-human primates for this vaccine candidate were published in April 2022. In August 2022, a phase 2 trial of 1 or 2 doses of AdCLD-CoV19-1 was registered.
prov:wasDerivedFrom
wikipedia-en:AdCLD-CoV19?oldid=1118148287&ns=0
dbo:wikiPageLength
4991
foaf:isPrimaryTopicOf
wikipedia-en:AdCLD-CoV19